Validation and Greenness assessment of UPLC Method for bioanalysis of Bilastine in mice PK study

Abstract

Bilastine, is a second-generation antihistamine drug which is used in the treatment of allergic rhinoconjunctivitis and urticaria. It exerts its effect as a selective histamine H₁ receptor antagonist. In this study, an ultra-high-performance liquid chromatography (UPLC) method was developed to measure the concentrations of Bilastine in mouse blood, and the method was applied in measuring the pharmacokinetics of the analyte after oral and intravenous administration. The analyte was extracted by solid phase extraction method. A UPLC BEH C18 column (2.1 mm × 100 mm, 1.8 ?m particle size) was used for chromatographic separation by gradient elution using acetonitrile-water (0.1% formic acid) as the mobile phase at a flow rate of 0.4 mL/min. Bilastine was administered to the mice orally at 2 mg/kg and intravenously at 0.05 mg/kg. Blood was collected at various time intervals, and the blood samples were processed after collection and analyzed by UPLC. The intra-day and inter-day accuracy of Bilastine were 91%-103% and 85%-107%, respectively, and the precision (RSD, %) was less than 15% for both intra-day and inter-day measurements. The matrix effect ranged from 95% to 108%, and the recovery was higher than 70%. The half-life of bilastine in plasma was found to be 7.02 ± 5.21h. Bilastine has a good linear relationship in the range of 10-500 ng/mL, and the lower limit of quantification was 10 ng/mL. The precision, accuracy, extraction recovery, matrix effect, and stability meet the requirements of the guiding principles. A robust and reliable UPLC method was fully optimized and developed to detect the blood concentration of bilastine in mice and the samples were analyzed by Empower software.